Single Nucleotide Polymorphisms and Colorectal Cancer Risk: The First Replication Study in a South American Population by Gomy, Israel et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Chapter 3
Single Nucleotide Polymorphisms and Colorectal
Cancer Risk: The First Replication Study in a South
American Population
Israel Gomy, Ligia Petrolini de Oliveira and
Benedito Mauro Rossi
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/intechopen.69994
Abstract
Colorectal cancer (CRC) heritability is determined by the complex interaction between 
inherited variants and environmental factors. CRC incidence rates have been increasing 
specially in developing countries, such as Brazil, where CRC is the third most frequent 
cancer in both genders. Genome‐wide association studies (GWAS), based on thousands of 
cases and controls typed at thousands of single nucleotide polymorphisms (SNPs), have 
identified several variants that associate with gastrointestinal cancer risk. Less of half 
of the familial risk has been elucidated through GWAS that identified common SNPs in 
almost exclusively European populations. Replication studies in admixed heterogeneous 
populations are scarce and most failed to replicate all the imputed SNPs. Population 
stratification by ethnic subgroups with different allele frequencies and so with differ‐
ent patterns of linkage disequilibrium may cause expurious associations. Here, we show 
the first replication study of CRC inherited susceptibility in South America and aimed 
to identify known SNPs, which are associated with CRC risk in European populations.
Keywords: cancer susceptibility, cancer risk, colorectal cancer, single nucleotide polym-
orphism, South America
1. Introduction
1.1. Epidemiology
Colorectal cancer (CRC) is one of the most prevalent cancers in both genders worldwide, 
responsible for about 10% of all neoplasms, mainly in developed industrialized countries, 
such as Australia and New Zeland, North America, and Europe [1].
© 2017 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
The variation in the CRC global incidence rates is progressively decreasing, and the increase 
of new cases in historically low incidence populations, such as Asian, seems to come along 
with a greater economic development and, consequently, a greater exposure to risk factors 
so‐called “Western lifestyle.” The highest incidence rates are in countries such as Australia, 
New Zealand, and in Western Europe, whereas the lowest incidence rates are in Africa and 
Southern Asia [2].
However, in developing countries such as Russia, Mexico, Chile, and Brazil, there is an increase 
of CRC incidence rates, possibly reflecting their population’s lifestyles and the increased life 
expectancy, as well as the improved data records, the insufficient public health policies for 
CRC screening, and the lack of population awareness.
Data from international registries indicate that the overall 5‐year survival rate is on average 55% 
in developed countries and 40% in developing countries and is higher in women than in men [3].
According to estimates from the National Cancer Institute for the 2016/2017 biennium, in Brazil, 
34,280 individuals will develop CCR (17,620 women and 16,660 men), corresponding to the 
second most common malignancy in women and third most common malignancy in men [4].
The detection and early removal of premalignant lesions reduces CRC mortality as con‐
firmed by several studies that have screened populations at general risk using the fecal occult 
blood test. In addition, the use of flexible sigmoidoscopy for screening has shown promising 
results in randomized trials in the United Kingdom [5] and the United States [6], where sig‐
nificant reductions in both incidence and mortality were observed. Improved survival was 
also observed with this approach in genetically determined high-risk groups [7]. Therefore, 
for those determined high-risk individuals could be offered a more intensive surveillance, 
with colonoscopy or flexible sigmoidoscopy periodically at shorter intervals. Colonoscopy is 
already offered to individuals at high risk due to personal or familial history of CRC, as well 
as for families with Lynch syndrome and intestinal polyposis syndromes, for which more 
assiduous surveillance is recommended [8]. Therefore, stratifying the general population into 
risk categories would allow the individualization of screening and prevention strategies.
1.2. Molecular pathogenesis
The classic adenoma‐carcinoma sequence has revealed an intricate molecular pathogenesis of 
CRC, where tumor suppressor genes are inactivated, and proto‐oncogenes are activated through 
several signaling pathways, such as APC‐B‐cathenin, RAS‐RAF, PIK3CA‐PTEN, and TGF‐B [9].
Three main molecular mechanisms are involved in CRC pathogenesis: chromosomal insta‐
bility, microsatellite instability, and serrated polyp pathway. The first one occurs in most 
sporadic cancers where the accumulation of mutations, rearrangements, and aneuploidy 
drives malignant transformation within decades [10]. The second one occurs in about 15% 
of sporadic CRC and in most hereditary CRC. In sporadic CRC, an epigenetic event—hyper‐
methylation—occurs in CpG islands of MMR gene promoters, which silences them leading to 
a genetic instability in microsatellite regions of genome [11]. In Lynch syndrome, mutations 
in MMR genes lead to microsatellite instability and accelerate adenoma‐carcinoma sequence 
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more rapidly, the reason why Lynch syndrome families develop cancer in their 40’s or even 
earlier. The most recently serrated polyp pathway involves molecular mechanisms other than 
the classic adenoma‐carcinoma sequence but has not yet been fully elucidated [12].
1.3. Risk factors
Colorectal carcinoma is a multifactorial disease, where complex interactions between genetic 
and environmental factors determine individual risk. Among the latter are diets rich in red 
meat and animal fat and lower in fiber, smoking, alcohol consumption, obesity, sedentary 
lifestyle, and chronic inflammatory bowel disease [13]. In addition to age, gender, and previ‐
ous history of polyps, familial history is considered the main risk factor, being the relative risk 
between siblings two to three times higher than in the general population [14].
Traditionally, CRC has been classified into sporadic and hereditary. The concept of familial 
CRC reflects one end of a risk spectrum determined by the contribution of genetic variants 
of susceptibility. Most are sporadic with no family history and known genetic susceptibil‐
ity. Most of the CRC susceptibility genes were identified in families affected by inherited 
syndromes, which are caused by mutations with high penetrance. These syndromes account 
for about 6% of CRC cases and can be classified as syndromes with or without gastrointes‐
tinal polyposis [15]. Among the main syndromes with polyposis are familial adenomatous 
polyposis (FAP) caused by mutations in the APC gene; Peutz-Jeghers syndrome, attributable 
to mutations in the STK11 gene; Juvenile polyposis, associated with the BMPR1A gene, and 
Cowden’s syndrome, related to the PTEN gene. Among non‐polyposis syndromes, the most 
prevalent is Lynch’s syndrome, accounting for about 3% of all the cases with CRC, caused 
by mutations in the mismatch repair genes during DNA replication (MLH1, MSH2, MSH6, 
PMS2, and EPCAM) [16].
Most of the mutations identified in familial CRC are highly penetrant, that is, with a high 
chance of manifesting cancer throughout the life. However, there are families with CRC clus‐
ters that do not have mutations in genes associated with hereditary syndromes. This raises 
the hypothesis that there are other variants or mutations with low penetrance that make cer‐
tain individuals more susceptible to the CRC development. Studies with brothers with and 
without CRC, as well as several association studies, have identified regions in the human 
genome in which single nucleotide polymorphisms (SNPs) variants are associated with CRC 
susceptibility [17].
Up to 25% of cases are familial CRC aggregations whose heritability has been partially 
uncovered by GWAS SNPs [18]. However, the large proportion of familial risk remains unex‐
plained—so‐called missing heritability.
1.4. Single nucleotide polymorphisms
Single nucleotide polymorphisms (SNPs) are variations of the human genome, where two or 
occasionally three alternative nucleotides are common in the population. In most cases, an SNP 
has two alternative forms, termed alleles, for example, A or G at a certain position in the genome.
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There are 10 million SNPs estimated in the human genome, representing, along with other 
types of polymorphisms (such as copy number variations), about 90% of human genetic varia‐
tion, including susceptibility to disease. Two individuals are 99.5% identical in their DNA 
sequences, and, every 1000 base pairs, there is one SNP [19].
Variants that have been deleterious during evolution are particularly rare due to natural 
selection. In turn, pathogenic variants that are deleterious in homozygosis may have become 
neutral or undergo a selection balance by conferring an advantage on asymptomatic heterozy‐
gotes. Therefore, alleles of frequent SNPs are not expected to have any significant phenotypic 
effect, either because natural selection would be in charge of eliminating it, - if it were detri‐
mental by negative selection -, or fixing it, if beneficial by positive selection. Moreover, most 
SNPs are not located in either coding or regulatory sequences but in intergenic sequences [20].
1.5. Genome‐wide association studies
Searching for population associations is an attractive option to identify disease susceptibil‐
ity genes. Association studies are easier to conduct than linkage studies because they do not 
require multiple family cases segregating the phenotype. However, they depend on the link‐
age disequilibrium (LD)—the nonrandom association between alleles at different loci—with 
a susceptibility factor, which can only be identified by markers located in the same haplotype 
block (the set of alleles at a linked locus in a single chromosome) close to the factor [21].
SNPs are the markers of choice for studying LD for three reasons: (1) they are sufficiently 
abundant that they allow verifying very short chromosome segments; (2) compared to mic‐
rosatellites, they have a lower mutation rate; (3) SNPs are easily large‐scale genotyped on 
genome [20].
The structure of the human LD was investigated by the HapMap project, and the first result 
was a list of more than 3 million SNPs that captured most of the common genomic variation 
in some populations [22].
Genome-wide association studies (GWAS) are based on the LD principle at the population 
level, which is usually the result of a particular ancestral haplotype common in a population. 
Usually, loci that are physically close exhibit a stronger DL than those that are distant in a 
chromosome. The genomic distance at which LD decays determines how many genetic mark‐
ers are required to “tag” a haplotype block, being the number of such markers much smaller 
than the total of segregating variants in the population. For example, the selection of about 
500,000 common SNPs in the human genome is sufficient to “tag” the common variants in 
non‐African population, even though the total SNPs are greater than 10 million [22]. These 
SNPs are called tagSNPs.
Although GWAS are not influenced by prior biological knowledge or genomic location of 
SNPs, they are influenced by LD between genotyped SNPs and non-genotyped causative 
variants. The strength of the statistical association between the alleles at the two loci in the 
genome depends, mainly, on their allelic frequencies. Thus, a rare variant—minor allele fre‐
quency (MAF) less than 0.01—will be low LD with a neighboring common variant, even 
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though they are in the same recombination range. However, most of the SNPs selected in the 
SNP arrays are common (MAF higher than 0.05), and therefore, GWASs have the power to 
detect association of variants that are relatively common in the population [21]. On the other 
hand, it is suggested that the observed association between a common SNP and a complex 
trait may result from LD of the SNP with rare variants at the same locus. Since common 
alleles and causal rare variants are correlated in a low LD, the hypothesis of a “synthetic 
association” implies that the magnitude of the effect of the causative variants is much greater 
than that of the common genotyped SNPs by the GWAS. For example, if an SNP explains 
0.1% of the phenotypic variance in the population, the causal variant would account for 
5–10% [23].
1.6. GWAS and CRC
Most of the studies to identify low penetrance alleles for CRC susceptibility were based 
on a candidate gene approach, whose role in CRC pathogenesis was supposedly known. 
However, without the real understanding of the biology of predisposition, the choice of 
genes was problematic. Thus, until the advent of GWAS, few or no association studies based 
on this approach were able to identify alleles of susceptibility unequivocally associated with 
the CRC risk [17].
To date, seven GWAS and three meta-analyses have identified about 20 independent loci 
associated with CRC susceptibility [24–34].
The number of common variants contributing with more than 1% of the inherited risk is very 
low, and it is very unlikely that there will be other SNPs with similar effects (greater than 
1.2) for alleles with frequencies greater than 20% in European populations. In fact, the GWAS 
identified on average 80% of the common SNPs in this population but only 12% of SNPs with 
a minor allele frequency (MAF) between 5 and 10% [17].
However, variants with this profile, if taken collectively, can confer substantial risks due to 
their multiplicity, and in the case of CRC, to date, explain about 10% of heritability [33]. In a 
model built on data from the Scottish GWAS, about 170 common independent variants would 
explain all the genetic variance of the CRC [35]. Therefore, most of the genetic susceptibility 
to CRC still needs to be defined the so-called “missing heritability”. There are other possible 
causes of this unidentified portion: (1) the effect of rare variants; (2) failure to identify causal 
variants; and (3) allelic heterogeneity [36].
GWAS strategies to identify modest common risk alleles are not ideal for identifying rare vari‐
ants (MAF below 1%) with potentially greater effects, as well as for capturing copy number 
variants and other structural variants, such as insertions, complex rearrangements, or expan‐
sions of microsatellite repeats, which may alter the risk of CRC. As efforts are made to scale 
up the GWAS meta‐analyses, both in terms of sample size and coverage of SNPs, as well as 
to increase the number of SNPs considered for large‐scale replication, it will be feasible to 
discover new variants. It is possible that a multiple loci approach based on haplotype markers 
identifies rare alleles. In addition, the use of exome sequencing may provide a more effective 
strategy for finding such variants [37].
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2. Objectives
The overall objective of the present study was to replicate in individuals of the Brazilian 
population the 10 SNPs associated with CRC risk that are previously described in European 
populations. The specific objectives were to (1) calculate the allelic and genotype frequencies 
of the 10 SNPs in cases and controls; (2) analyze the association between the genotypes and 
alleles of the 10 SNPs and CRC risk; (3) calculate the magnitude of the effect on CRC risk; and 
(4) correlate the genotypes of the 10 SNPs with clinical‐pathological characteristics and with 
familial history.
3. Research methods
3.1. Patient selection criteria
This is a retrospective study of case‐control genetic association, whose sample comprised 727 
cases and 740 controls, recruited from the Departments of Pelvic Surgery, Clinical Oncology, 
and Community Medicine at AC Camargo Cancer Center, in São Paulo, Brazil. All patients 
and controls authorized the present study by signing the informed consent form previously 
approved by the Research Ethics Committee of the institution under number 1231/09.
The inclusion criteria for cases were CRC diagnosis before age 75 years or with advanced 
colorectal adenoma (villous histology and/or greater than 1 cm and/or severe dysplasia) diag‐
nosis before age 60 years, and controls were individuals without CRC who did not have first- 
or second‐degree relatives with CRC. Controls were not matched with the cases in relation to 
the socioeconomic condition, ancestry, or self‐referred ethnicity. The exclusion criteria were 
the presence of hereditary syndromes of predisposition to CRC, immunohistochemistry tests 
showing absence of proteins from DNA mismatch repair genes, the presence of high‐pene‐
trance germline mutations in susceptible genes to CRC, and appendix tumors and/or previous 
chronic inflammatory bowel disease.
3.2. SNP genotyping
After consent form was signed, 8 ml of peripheral blood was drawn to extract, purify, quan‐
tify, and amplify DNA. Quantitative PCRs for 10 tagSNPs (rs6983267, rs4939827, rs4779584, 
rs16892766, rs10795668, rs4444235, rs9929218, rs10411210, rs961253, and rs3802842) were per‐
formed using TaqMan® SNP Genotyping Assays and 7900HT Fast Real‐Time PCR System 
(Thermo Scientific Fisher, CA, USA). Allelic discrimination analyses were made using the 
Sequence Detection Systems Automation Controller Software v2.3 and the auto‐calling tech‐
nique (Thermo Scientific Fisher, CA, USA).
As genotyping quality control, genotypes with the following criteria were excluded: (1) over‐
all call <95%; (2) discordant duplicates; (3) Hardy‐Weinberg imbalance (p < 10−6 in cases and 
p < 10−4 in controls); and (4) clusters of unsatisfactory genotypes in the X:Y axis inspection.
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3.3. Statistics analysis
All tests were corrected for multiple analyses to avoid type I error. The allelic and genotypic 
frequencies of each SNP were calculated using the DeFinetti program [38], and the deviations 
of the genotype frequencies in cases and controls predicted by the Hardy‐Weinberg equilib‐
rium were calculated by the chi-square test with one degree of freedom or by Fisher’s exact 
test, if the expected cell count was less than five.
Association analyses between the genotypes found in cases and controls for each SNP 
were performed with several types of genetic models, using the SNP and Variation Suite 
Version 7.6.10 program [39]. Multiple analyses were corrected by false discovery rate and 
Bonferroni.
4. Results
4.1. Clinical characteristics of cases and controls
Of the 727 cases included in this study, 51% were male, with a median age of diagnosis 
of 56.9 ± 10.1 SD years old; 30% fulfilled Bethesda criteria; 3% of tumors were high-risk 
adenomas; the most common site of CRC was the rectum and in about 10%, there was an 
extra-colonic second primary tumor; tubular adenocarcinomas moderately differentiated at 
clinical stage III was mostly diagnosed. The majority of patients was alive disease-free until 
data collection and about 30% of cases had no familial history of CRC, despite almost 20% 
did not know about affected relatives. Of the 740 controls included in this study, 52% were 
female, with a median age of 51.9 ± 12.3 SD years old. Cases and controls were age and sex 
matched (p = 0.126 and 0.193, respectively).
4.2. SNP genotyping and association tests
The genotypic frequencies of each SNP in cases and controls and their p‐values are depicted 
in the following graphics:
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The allelic frequencies, the number of alleles, the genotyping rate, and the Hardy‐Weinberg 
equilibrium (EHW) test are represented in Table 1.
The genetic association tests and their genetic models are shown in Table 2.
Of the 10 SNPs, 5 (06, 09 16, 82, and 83) were statistically significant (p ≤ 0.05) associated with 
the risk of CRC and 2 (26 and 71) showed a trend to association (p < 0.1). SNP 06 showed the 
more significant association among all SNPs in all genetic models. SNP 09 was the only pre‐
dictor of low risk, mainly in the dominant model (25% lower), whereas SNPs 16 and 82 were 
associated with high risk in the recessive model (45 and 85% higher, respectively). SNP 83 
had higher risk principally in the dominant model (almost 50%). SNPs 26 and 71, on the other 
hand, obtained a marginally significant association only in the allelic and additive models, 
with a trend toward a higher risk with SNP 71 and lower risk with SNP 26. To sum up, of 
five SNPs associated with CRC risk, two (SNP 16 and 82) conferred higher risk among rare 
homozygotes than among heterozygotes and common homozygotes together through the 
recessive model and three (06, 09, and 83) showed higher risk among heterozygotes and rare 
homozygotes together than among common homozygotes through the dominant model.
Table 3 shows the five SNPs associated with CCR risk with their respective wild and variant 
alleles, their risk allele frequencies in comparison with the European population, the effect 
size of the variant allele and the their populational attributable risks, which is the incidence 
decrease of disease if the population was not exposed to the risk allele.
5. Discussion
In common diseases, such as CRC, it estimated that the most part of its genetic risk is due to the 
inherited multiple loci following polygenic model, each one with a common allelic frequency 
(MAF greater than 5%), whose effects show small sizes, between odds ratios 1.0 and 1.5. [17] 
Thus, to detect those small effects, it is necessary a big sample size. This strategy was validated 
by metanalyses of GWAS data from European populations with tens of thousands genotyped 
individuals through high throughput platforms, followed by validation by multiple phases 
with independent series of cases and controls. Even though only about 20 common SNPs with 
modest effects were identified so far, each one with a p value corrected by multiple tests (<5.0 × 
10−8). In Table 4, GWAS data from European populations are compared to this study.
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EHW test Allelic frequencies Number of alleles Frequencies Genotyping rate
Cases Controls Cases Controls Cases Controls Cases Controls Global
SNP p p Major 
allele
Minor 
allele
Major 
allele
Minor 
allele
Major 
allele
Minor 
allele
Major 
allele
Minor 
allele
Major 
allele
Minor 
allele
% % %
rs4939827 
(SNP06)
0.7018 0.0978 0.48 0.52 0.57 0.43 658 710 838 632 0.53 0.47 94.1 99.3 96.7
rs10411210 
(SNP09)
0.0007 0.7158 0.84 0.16 0.81 0.19 1213 229 1205 275 0.83 0.17 99.2 100.0 99.6
rs4444235 
(SNP16)
0.1565 0.9411 0.48 0.52 0.53 0.47 689 755 791 689 0.51 0.49 99.3 100.0 99.7
rs9929218 
(SNP21)
0.9279 0.9273 0.71 0.29 0.72 0.28 1021 417 1064 414 0.72 0.28 98.9 99.9 99.4
rs4779584 
(SNP26)
0.2319 0.3270 0.74 0.26 0.71 0.29 1030 356 1050 430 0.73 0.27 95.3 100.0 97.7
rs961253 
(SNP45)
0.5022 0.3750 0.66 0.34 0.65 0.35 946 480 960 520 0.66 0.34 98.1 100.0 99.0
rs10795668 
(SNP59)
0.0576 0.2311 0.73 0.27 0.72 0.28 1041 385 1072 408 0.73 0.27 98.1 100.0 99.0
rs6983267 
(SNP71)
0.8151 0.7557 0.58 0.42 0.62 0.38 804 580 913 567 0.60 0.40 95.2 100.0 97.6
rs3802842 
(SNP82)
0.1146 0.7613 0.71 0.29 0.76 0.24 984 398 1127 353 0.74 0.26 95.0 100.0 97.5
rs16892766 
(SNP83)
0.1287 0.0005 0.9 0.10 0.93 0.07 1265 135 1369 105 0.92 0.08 96.3 99.6 98.0
Table 1. Allelic frequencies, number of alleles, genotyping rate and Hardy‐Weinberg equilibrium (EHW) test.
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Models SNP Risk allele 
(minor)
RAF Allelic OR 
[95% CI]
p Dominant OR 
[95% CI]
p Recessive OR 
[95% CI]
p Additive OR 
[95% CI]
p
rs4939827 (SNP 
06)
C 0.47 1.43 
[1.23–1.66]
2.12 × 10–5 1.67 
[1.33–2.11]
0.0001 1.51 
[1.18–1.93]
0.011 1.54 
[1.20–1.98]
3.49 × 10−5
rs10411210 
(SNP 09)
T 0.17 0.83 
[0.68–1.00]
0.080 0.75 
[0.60–0.94]
0.040 1.19 
[0.70–2.01]
0.749 0.71 
[0.56–0.90]
0.083
rs4444235 
(SNP16)
C 0.49 1.26 
[1.09–1.45]
0.011 1.26 
[1.00–1.60]
0.097 1.45 
[1.14–1.83]
0.012 1.38 
[1.07–1.78]
0.012
rs3802842 (SNP 
21)
A 0.26 1.29 
[1.09–1.53]
0.010 1.26 
[1.02–1.56]
0.072 1.85 
[1.23–2.78]
0.009 1.69 [1.1 
–2.60]
0.011
rs16892766 
(SNP 26)
C 0.08 1.39 
[1.07–1.82]
0.038 1.49 
[1.11–1.99]
0.035 0.96 
[0.40–2.27]
0.920 1.55 
[1.14–2.10]
0.049
rs6983267 (SNP 
45)
T 0.40 1.16 
[1.00–1.35]
0.086 1.18 
[0.95–1.46]
0.2 1.29 
[0.97–1.72]
0.188 1.23 
[0.91–1.66]
0.082
rs4779584 (SNP 
59)
T 0.27 0.84 
[0.72–1.00]
0.089 0.82 
[0.66–1.00]
0.092 0.80 
[0.55–1.17]
0.498 0.83 
[0.67–1.04]
0.097
rs9929218 (SNP 
71)
A 0.28 1.05 
[0.89–1.23]
0.629 1.05 
[0.85–1.29]
0.645 1.11 
[0.76–1.62]
0.737 1.03 
[0.83–1.28]
0.628
rs961253 (SNP 
82)
A 0.34 0.94 
[0.80–1.09]
0.515 0.93 
[0.76–1.15]
0.623 0.90 
[0.66–1.22]
0.824 0.95 
[0.76–1.18]
0.524
rs10795668 
(SNP 83)
A 0.27 0.97 
[0.83–1.14]
0.739 0.95 
[0.77–1.17]
0.682 1.02 
[0.71–1.48]
1 0.94 
[0.75–1.17]
0.739
RAF, risk allele frequency.
Table 2. Genetic association tests and genetic models.
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SNP Wild allele* Risk allele Risk allele 
frequencies(RAF)
Minor allele 
frequency 
(Europeans)*
Effect size Populational 
attributable 
risk** (%)
rs4939827 (SNP 06) T (major) C (minor) 0.47 0.47 43% higher 16.8
rs10411210 (SNP 09) C (major) T (minor) 0.17 0.10 25% lower –
rs4444235 (SNP 16) T (major) C (minor) 0.49 0.48 26% higher 11.3
rs3802842 (SNP 82) C (minor) C (minor) 0.26 0.27 29% higher 7.0
rs16892766 (SNP 83) A (major) C (minor) 0.08 0.09 39% higher 3.0
* From 1000 genomes.
** (RAF(OR – 1))/(1 + RAF(OR – 1)).
Table 3. The five SNPs associated with CCR risk.
SNP Risk allele RAF Effect size (odds 
ratio)
PAR (%) Sample size 
(total)
References
rs4939827 
(SNP 06)
C (major) 0.52 1.18 8.6 15,362 Broderick et al. [27]
rs10411210 
(SNP 09)
T (minor)
C (major)
0.10
0.90
0.87
1.15
–
11.9
41,259 Houlston et al. [31]
rs4444235 
(SNP 16)
C (minor) 0.46 1.11 4.8 41,259 Houlston et al. [31]
rs9929218 
(SNP 21)
G (major) 0.71 1.10 6.6 41,259 Houlston et al. [31]
rs4779584 
(SNP 26)
T (minor) 0.18 1.26 4.5 14,663 Jaeger et al. [28]
rs961253 (SNP 
45)
A (minor) 0.36 1.12 4.0 41,259 Houlston et al. [31]
rs10795668 
(SNP 59)
G (major) 0.67 1.12 7.4 37,371 Tomlinson et al. [30]
rs6983267 
(SNP 71)
G (major) 0.51 1.21 9.7 14,470 Tomlinson et al. [25]
rs3802842 
(SNP 82)
C (minor) 0.29 1.12 3.4 27,794 Tenesa et al. [29]
rs16892766 
(SNP 83)
C (minor) 0.07 1.25 1.7 37,371 Tomlinson et al. [30]
RAF, risk allele frequency; PAR, populational attributable risk.
Table 4. GWAS data from European populations compared to this data.
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In this study, there was an association with CRC risk in half of SNPs (06, 09 16, 82 and 83), 
whose risk alleles revealed similar frequencies as to European GWAS, except SNP 06. Effect 
sizes were modest as well as European GWAS. SNP 06 was the variant that resulted the greatest 
effect with the most statistically significant association (p
trend
 = 3.49 × 10−5), which conferred the 
highest populational risk, whereas in European GWAS, the risk augmented up to 23%, repre‐
senting 8.6% of the populational risk [35]. In the original study, the same SNP also showed the 
greatest association (p
trend
 = 1.0 × 10−12) [27]. SNP 09 (rs10411210) was associated with a low risk 
in a dose‐dependent way [31]. In this study, however, this effect was detected only in the domi‐
nant model. It is noteworthy that in European studies the major allele (C) confers 15% higher 
risk, responsible for 12% of the populational risk [35]. In the present study, there was a trend to 
a higher risk but not statistically significant (p = 0.08). Moreover, SNP 16 was associated with 
a higher risk in this study than from European GWAS, as well as the populational attributable 
risk [35]. Likewise, SNPs 82 and 83 also increased more the CRC risk and populational risk in 
the present study than from European GWAS [35].
In the present study, the populational stratification by ancestry was not investigated. 
However, the Brazilian population, although greatly admixed, has a high prevalence of indi‐
viduals from European ancestry, whose the great majority is located in the South (79.5%) and 
Southeast (74.2%) [40].
6. Conclusion
This study partially replicated European GWAS in Brazilian Southeastern population with a 
predominantly European genetic background. Small sample size and lack of stratification by 
ancestry are prone to type I and II errors, respectively. Further studies in admixed popula‐
tions would certainly aid to uncover the missing heritability of CRC and help to build the 
genetic architecture of CRC susceptibility.
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